Landmark lipid-lowering trials in the primary prevention of cardiovascular disease

Jonathan Chrispin, Seth S. Martin, Rani K. Hasan, Parag H. Joshi, C. Michael Minder, John W. McEvoy, Payal Kohli, Amber E. Johnson, Libin Wang, Michael J. Blaha, Roger S. Blumenthal

Research output: Contribution to journalReview article

Abstract

Although atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality in the world, the long disease latency affords ample opportunity for preventive care. Indeed, lifelong exposure to atherogenic apoliprotein B-containing lipoproteins has consistently been shown to increase the cumulative risk of suffering a CVD event, including myocardial infarction, stroke, and symptomatic peripheral arterial disease. Over the past 25 years, lipid-lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse CVD events and CVD mortality. This review will highlight several key clinical trials encompassing several classes of lipid-lowering medications that have provided clinicians with an evidence-based framework for managing their patients' cardiovascular risk.

Original languageEnglish (US)
Pages (from-to)516-523
Number of pages8
JournalClinical Cardiology
Volume36
Issue number9
DOIs
StatePublished - Sep 1 2013

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Landmark lipid-lowering trials in the primary prevention of cardiovascular disease'. Together they form a unique fingerprint.

  • Cite this